| HIVsir ID | HIV Strain | NCBI Accession | Target Gene | Position of siRNA target | Sense Sequence of siRNA | Efficacy (%) | Target Conservation * | Cell line | PubMed |
| 1060 | HIV-1 (NL4-3) | AF324493 | Nef | 8834 | AAGGGAAAGAAUGAGACGAGC | 49.00 | 97(6.48%) | 293 T | 15564478 |
| 1061 | HIV-1 (NL4-3) | AF324493 | Nef | 9059 | AAAAGAAAAGGGGGGACUGGA | 63.00 | 1213(81.08%) | 293 T | 15564478 |
| 1062 | HIV-1 (NL4-3) | AF324493 | Nef | 9139 | AAGGCUACUUCCCUGAUUGGC | 48.00 | 493(32.95%) | 293 T | 15564478 |
| 1195 | HIV-1 (LAI) | K02013 | Nef | 8656 | CUUUUUAAAAGAAAAGGGG | 54.00 | 1159(77.47%) | 293 T | 16959541 |
| 1196 | HIV-1 (LAI) | K02013 | Nef | 8657 | UUUUUAAAAGAAAAGGGGG | -13.00 | 1210(80.88%) | 293 T | 16959541 |
| 1197 | HIV-1 (LAI) | K02013 | Nef | 8658 | UUUUAAAAGAAAAGGGGGG | -6.00 | 1417(94.72%) | 293 T | 16959541 |
| 1198 | HIV-1 (LAI) | K02013 | Nef | 8659 | UUUAAAAGAAAAGGGGGGA | 5.00 | 1418(94.79%) | 293 T | 16959541 |
| 1199 | HIV-1 (LAI) | K02013 | Nef | 8660 | UUAAAAGAAAAGGGGGGAC | -20.00 | 1211(80.95%) | 293 T | 16959541 |
| 1200 | HIV-1 (LAI) | K02013 | Nef | 8661 | UAAAAGAAAAGGGGGGACU | 8.00 | 1215(81.22%) | 293 T | 16959541 |
| 1201 | HIV-1 (LAI) | K02013 | Nef | 8662 | AAAAGAAAAGGGGGGACUG | -14.00 | 1216(81.28%) | 293 T | 16959541 |
| 1202 | HIV-1 (LAI) | K02013 | Nef | 8663 | AAAGAAAAGGGGGGACUGG | -5.00 | 1215(81.22%) | 293 T | 16959541 |
| 1203 | HIV-1 (LAI) | K02013 | Nef | 8664 | AAGAAAAGGGGGGACUGGA | -21.00 | 1221(81.62%) | 293 T | 16959541 |
| 1421 | HIV-1 (LAI) | K02013 | Nef | 8664 | AAGAAAAGGGGGGACUGGA | 61.00 | 1221(81.62%) | 293 T | 19384894 |
| 1569 | HIV-1 (NL4-3) | AF324493 | Nef | 8950 | GUGCCUGGCUAGAAGCACA | 15.00 | 270(18.05%) | SupT | 18727943 |
| 1007 | HIV-1 (NL4-3) | AF324493 | Nef | 8950 | GUGCCUGGCUAGAAGCACA | 95.90 | 270(18.05%) | Magi | 12087358 |
| 1048 | HIV-1 (NL4-3) | AF324493 | Nef | N/A | TTCCAGTCACACCTCAGGTAC | 6.00 | 10(0.67%) | 293 T | 15336659 |
| 1063 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGGCAAGUGGUCAAAACGUA | 48.30 | 0(0.00%) | MT-4 T/Jurkat T | 15601474 |
| 1064 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGCCAGCAGCAGAUGGGGUG | 36.50 | 1(0.07%) | MT-4 T/Jurkat T | 15601474 |
| 1065 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGUGCCUGGCUAGAAGCACA | 78.40 | 1(0.07%) | MT-4 T/Jurkat T | 15601474 |
| 1066 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGCACAAGAGGAGGAGA | 70.90 | 0(0.00%) | MT-4 T/Jurkat T | 15601474 |
| 1067 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGACUGGAAGGGCUAAUUUG | 50.50 | 0(0.00%) | MT-4 T/Jurkat T | 15601474 |
| 1068 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCUCGACGGCUACUUCCCUGAUUGGC | 65.50 | 0(0.00%) | MT-4 T/Jurkat T | 15601474 |
| 1069 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGGUAGAAGAGGCCAAUGAA | 58.00 | 0(0.00%) | MT-4 T/Jurkat T | 15601474 |
| 1070 | HIV-1 (IIIB) | EU541617 | Nef | N/A | GCGUCGACGCAUUUCAUCACAUGGCCC | 48.30 | 2(0.13%) | MT-4 T/Jurkat T | 15601474 |
| 1071 | HIV-1 (LAI) | K02013 | Nef | 8553 | GUGCCUGGCUAGAAGCACA | 90.00 | 270(18.05%) | SupT1 | 15687388 |
|